H.C. Wainwright Reiterates Buy Rating on Akero Therapeutics (AKRO), HARMONY Trial Results Remain Key Catalyst
Tweet Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $62.00 price target on Akero Therapeutics (NASDAQ: AKRO), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
